Tulsa Wealth Advisors INC Buys Shares of 7,264 DexCom, Inc. $DXCM

Tulsa Wealth Advisors INC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, HoldingsChannel.com reports. The fund bought 7,264 shares of the medical device company’s stock, valued at approximately $489,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Reflection Asset Management bought a new stake in shares of DexCom during the 4th quarter worth approximately $25,000. Ascentis Independent Advisors bought a new position in DexCom in the 1st quarter valued at $25,000. MCF Advisors LLC bought a new position in DexCom in the 4th quarter valued at $32,000. Wellington Grp LLC increased its stake in DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares during the period. Finally, DV Equities LLC purchased a new stake in DexCom in the fourth quarter worth $36,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $89.75 on Monday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $91.96. The firm has a market cap of $33.87 billion, a PE ratio of 35.47, a price-to-earnings-growth ratio of 1.51 and a beta of 1.41. The business has a fifty day simple moving average of $76.08 and a two-hundred day simple moving average of $70.34. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.48 EPS. Analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, Director Mark G. Foletta sold 2,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the sale, the director directly owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president owned 106,353 shares in the company, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 99,794 shares of company stock valued at $7,373,321 in the last ninety days. 0.28% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on DXCM. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Mizuho upped their price target on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Weiss Ratings raised shares of DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Barclays reiterated an “underweight” rating and set a $64.00 price objective (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Finally, Bank of America lowered their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.